Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Declercq J (COV-AID)
  NCT04330638		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
114/115 inconclusive
    RCT-TCZ-COVID-19
          NCT04346355    		 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
    		60/66 inconclusive
      RECOVERY
              NCT04381936      		 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      		2022/2094 conclusif
      • demonstrated 15 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 15 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
      Rutgers RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      		174/180 suggested
      • inconclusive 41 % decrease in death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 35 % decrease in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
      Soin AS (COVINTOC)
              CTRI/2020/05/025369      		 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
      		90/90 inconclusive
        Dongsheng Wang
                  ChiCTR2000029765        		 RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
        		33/32 safety concern
        • statistically significant 8.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
        EMPACTA
                  NCT04372186        		 RCTtocilizumab placeboCOVID 19 hospitalizedsome concern
        		259/129 conclusif
        • demonstrated 44 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
        • suggested 45 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
        EU-CTR2020-001375-32 (PreToVid) unpublished
                  EU-CTR2020-001375-32        		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
        		174/180 inconclusive
          EU-CTR2020-001748-24 (ImmCoVA) unpublished
                      EU-CTR2020-001748-24          		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
          		22/27 inconclusive
            NCT04412772 (ARCHITECTS) unpublished
                          NCT04412772            		 RCTtocilizumab placeboCOVID 19 hospitalizedlow
            		10/11 inconclusive
              NCT04434717 (COVITOZ-1 single dose plus two doses) unpublished
                              NCT04434717              		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
              		17/9 inconclusive
                NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg) unpublished
                                  NCT04479358                		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
                		20/8 inconclusive
                  NCT04577534 (COVIDSTORM) unpublished
                                      NCT04577534                  		 RCTtocilizumab standard of careCOVID 19 hospitalizedlow
                  		26/13 inconclusive

                    COVID 19 all comers meta-analysis

                    BACC Bay Tocilizumab Trial
                                          NCT04356937                    		 RCTtocilizumab placeboCOVID 19 all comerslow
                    		161/81 inconclusive
                    • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias

                    COVID-19 severe or critically meta-analysis

                    MARIPOSA
                                          NCT04363736                    		 RCTtocilizumab tocilizumab COVID-19 severe or criticallysome concern
                    		48/49 inconclusive
                      A trend for increased progression toward worse clinical status (categories 5 and 6) and death (category 7) was seen up to day 14 for the 4-mg/kg vs 8-mg/ kg group, followed by no notable difference between groups at days 21 and 28.
                      REMAP-CAP (tocilizumab)
                                              NCT02735707                      		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                      		353/402 conclusif
                      • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
                      • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
                      Rosas (REMDACTA)
                                              NCT04409262                      		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
                      		434/215 inconclusive
                      • inconclusive 3 % decrease in hospital discharge (PE) with a moderate degree of certainty due to some concern in risk of bias
                      Talaschian
                                              IRCT20081027001411N4                      		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                      		20/20 inconclusive
                        Veiga
                                                  NCT04403685                        		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                        		65/64 safety concern
                        • safety concern with 1.7-fold increase in deaths,death D28 (not statistically significant)
                        • inconclusive 54 % increase in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
                        CORIMUNO-TOCI-1 (Group 1)
                                                  NCT04331808                        		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                        		64/67 inconclusive
                          CORIMUNO-TOCI-ICU (Group 2)
                                                      NCT04331808                          		 RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
                          		49/43 inconclusive
                            COVACTA (Rosas)
                                                          NCT04320615                            		 RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
                            		301/151 suggested
                            • inconclusive 19 % increase in clinical improvement,clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
                            15 studies excluded by filtering options (4 RCT / 11 OBS)

                            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

                             

                            - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons